Gen-Probe (US) gets Transcription Mediated Amplification (TMA) patent
This article was originally published in Clinica
Gen-Probe (US) has received a US patent for Transcription Mediated Amplification (TMA). A Mycobacterium tuberculosis test based on the technique received a conditional approval recommendation from the US FDA advisory panel on May 2nd (see this issue p 15). A urine and urogenital sample-based Chlamydia trachomatis kit will enter clinical trials in the near future and tests for HIV viral RNA, hepatitis B virus DNA and leukaemia are in development.
You may also be interested in...
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.